Citadel Advisors
LXEO icon

Citadel Advisors’s Lexeo Therapeutics LXEO Stock Holding History

Citadel Advisors’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22M Buy
3,834,999
+60,682
+2% +$430K ﹤0.01% 2219
2025
Q4 		$37.5M Buy
3,774,317
+55,274
+1% +$504K 0.01% 1692
2025
Q3 		$24.7M Buy
3,719,043
+111,076
+3% +$537K ﹤0.01% 2069
2025
Q2 		$14.5M Buy
3,607,967
+884,604
+32% +$2.91M ﹤0.01% 2558
2025
Q1 		$9.45M Hold
2,723,363
– – ﹤0.01% 2934
2024
Q4 		$17.9M Hold
2,723,363
– – ﹤0.01% 2285
2024
Q3 		$24.6M Buy
2,723,363
+164,752
+6% +$1.96M ﹤0.01% 1838
2024
Q2 		$41M Buy
2,558,611
+55,630
+2% +$808K 0.01% 1308
2024
Q1 		$38.9M Buy
2,502,981
+418,736
+20% +$6.55M 0.01% 1415
2023
Q4 		$28M Buy
+2,084,245
New +$25.9M 0.01% 1697

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors's LXEO Position: Q1 2026 in Review

Citadel Advisors increased its Lexeo Therapeutics (LXEO) stake by 1.6% in Q1 2026, buying an estimated $430K and bringing the position to 3,834,999 shares worth $22M. The position accounts for ﹤0.01% of the portfolio, ranked #2219.

Citadel Advisors first reported a position in LXEO in Q4 2023 and has held it in 10 quarters since. The position peaked at $41M in Q2 2024. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Citadel Advisors held 3,834,999 shares of Lexeo Therapeutics worth $22M as of Q1 2026.
  • Citadel Advisors bought 60,682 Lexeo Therapeutics shares in Q1 2026, an estimated $430K.
  • Lexeo Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2219 holding.
  • Citadel Advisors first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Citadel Advisors's Lexeo Therapeutics position peaked at $41M in Q2 2024.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.